Performant Healthcare, Inc.

Performant Healthcare, Inc. (PHLT) Market Cap

Performant Healthcare, Inc. has a market capitalization of $611.6M.

Financials based on reported quarter end 2025-06-30

Price: $7.75

0.02 (0.26%)

Market Cap: 611.64M

NASDAQ · time unavailable

CEO: Simeon M. Kohl

Sector: Technology

Industry: Information Technology Services

IPO Date: 2024-12-03

Website: https://performantcorp.com

Performant Healthcare, Inc. (PHLT) - Company Information

Market Cap: 611.64M · Sector: Technology

Performant Healthcare, Inc. provides technology-enabled payment integrity, eligibility, and related analytics services. It supports healthcare payers in identifying, preventing, and recovering waste and improper payments through advanced technology, analytics, and proprietary data assets. The company offers coordination-of-benefits services, as well as claims-based services, which includes the audit and identification of improperly paid claims. It also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs to mitigate future instances of improper payments. The company was formerly known as Performant Financial Corporation and changed its name to Performant Healthcare, Inc. in December 2024. Performant Healthcare, Inc. was founded in 1976 and is headquartered in Plantation, Florida.

Analyst Sentiment

50%
Hold

Based on 4 ratings

Analyst 1Y Forecast: $7.75

Average target (based on 1 sources)

Consensus Price Target

Low

$8

Median

$8

High

$8

Average

$8

Potential Upside: 0.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PERFORMANT HEALTHCARE INC (PHLT) — Investment Overview

🧩 Business Model Overview

PERFORMANT HEALTHCARE INC (PHLT) operates in the healthcare services value chain by providing outcomes-oriented support services that help payers and providers improve the financial and operational performance of specific clinical and administrative workflows. The model typically follows a repeatable pattern: PHLT engages a customer (payer, provider, or delegated entity), defines measurable service scope and documentation/claims-related deliverables, executes against those deliverables through trained personnel and standardized processes, and then monetizes based on contracted terms that may include a mix of fixed service fees and performance-linked components.

Customer stickiness tends to come from the integration of PHLT’s teams and processes into the customer’s internal operations, including workflows, documentation requirements, reporting cadence, and operational handoffs. Over time, transitioning to another vendor introduces operational disruption and performance uncertainty, which elevates switching costs.

💰 Revenue Streams & Monetisation Model

PHLT’s monetization is best understood through a “service + execution” lens rather than a product sales model. Revenue generally divides into (1) recurring or semi-recurring service fees tied to ongoing operations and (2) transactional or performance-linked economics tied to outcomes within the service scope (e.g., documentation, administrative support, or process completion milestones).

Margin drivers are typically dominated by labor productivity, process standardization, and case/workflow throughput. In healthcare services, incremental economics usually improve when volumes scale without a proportional increase in overhead—provided quality and compliance requirements remain intact. Conversely, margin compression can occur if service mix shifts toward lower-margin work, if attrition forces higher rehiring/training costs, or if regulatory/documentation requirements become more complex.

🧠 Competitive Advantages & Market Positioning

The core moat for PHLT is primarily switching costs and process know-how, supported by intangible assets (institutional experience, compliance discipline, and established workflows) rather than a proprietary technology platform. Competitors can often replicate high-level service descriptions, but replicating operational execution—without triggering quality or compliance shortfalls—takes time and management attention.

  • Switching costs: Customers gain operational familiarity, reporting continuity, and embedded workflow integration after vendor onboarding; replacing a vendor risks service disruption and performance volatility.
  • Intangible assets: Documented processes, training playbooks, and compliance-oriented execution accumulate over cycles and are not easily transferable in the short run.
  • Customer-specific learning curves: Each account may have distinct operational constraints and documentation requirements, enabling a vendor with deeper account-specific experience to execute with higher efficiency and fewer rework loops.

Overall, the competitive positioning is defensible when PHLT can demonstrate consistent quality, audit-readiness, and stable delivery economics—factors that influence renewals and expansions more than advertised capabilities.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, PHLT’s opportunity is aligned to secular demand for healthcare administrative efficiency and quality improvement, driven by payer/provider pressure to manage costs and improve revenue capture consistency. Key growth vectors include:

  • Outsourcing and delegation trends: Payers and providers increasingly delegate complex administrative and documentation-related work to specialized partners to preserve internal capacity.
  • Complexity inflation: Evolving coding, documentation expectations, and compliance requirements expand the need for disciplined execution and continuous process management.
  • Account expansion: Once a vendor demonstrates performance within a defined scope, expansion to adjacent service lines or additional geographies/accounts becomes more feasible due to institutional learning and lower marginal onboarding friction.
  • Utilization and reimbursement dynamics: When healthcare systems face reimbursement pressure, demand can rise for services that improve the correctness and completeness of claims-related workflows.

TAM expansion is not solely dependent on industry growth; it also depends on PHLT’s ability to win and retain contracts in environments where customers prioritize measurable operational outcomes and compliance reliability.

⚠ Risk Factors to Monitor

  • Contract and reimbursement pressure: Performance-linked economics and pricing renegotiations can reduce realized margins if competitive bids commoditize service rates.
  • Regulatory and compliance risk: Healthcare workflows are sensitive to regulatory interpretation; execution failures can lead to reputational damage, contract terminations, or remediation costs.
  • Operational execution risk: Service quality depends on workforce stability, training rigor, and process control. Elevated turnover or scaling inefficiencies can lead to rework and margin erosion.
  • Technology substitution risk: Automation and workflow tools could compress demand for certain low-complexity tasks. PHLT must retain value through process mastery, audit readiness, and high-quality execution—not only data handling.
  • Capital and scalability constraints: Growth may require working capital and workforce ramp capacity; mismanagement can strain profitability even when contract demand is present.

📊 Valuation & Market View

Healthcare services companies are commonly valued using enterprise multiples that reflect service economics and growth visibility, such as EV/EBITDA or EV/Revenue (often alongside an assessment of margin durability and contract quality). The market generally rewards:

  • Durable gross-to-operating profit conversion: Stable margin performance indicates execution strength and operating leverage.
  • Renewal rates and backlog/contract visibility: Higher contract quality reduces earnings volatility.
  • Evidence of scalable delivery: Margin resilience during volume changes supports an “operating leverage” narrative.
  • Balanced growth: Growth that does not require disproportionate headcount or overhead is typically valued more favorably.

Multiple compression typically follows deterioration in margins, weakening contract economics, or increased compliance/operational incidents that raise perceived risk.

🔍 Investment Takeaway

PHLT’s long-term investment case rests on an operations-driven healthcare services model with structural switching costs and accumulated process know-how. If PHLT sustains quality and compliance execution while scaling delivery efficiency, the business can benefit from ongoing secular outsourcing and complexity-related demand. Key diligence priorities center on contract durability, margin resilience, and the durability of PHLT’s account-specific execution advantages versus increasing automation and competitive bidding.


⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-06-30

"PHLT reported revenue of $37.8M for the quarter ending June 30, 2025, with a net income of $2.1M and earnings per share (EPS) of $0.03. Operating cash flow stood at $430k, indicating limited cash generation relative to its operational needs. The company has total assets of $110.96M against liabilities of $28.72M, resulting in total equity of $82.24M. With net debt at $6k, PHLT appears to maintain a strong balance sheet; however, free cash flow is negative at -$867k, reflecting challenges in capital expenditure management. PHLT currently does not pay dividends, which may be atypical for companies of this size. Market performance data suggests no current share price, limiting insights into price appreciation. The focus on revenue growth and operational efficiency is essential, particularly given the current cash flow situation and the necessity to move towards positive free cash flow in future quarters."

Revenue Growth

Neutral

Moderate revenue for the quarter, showing potential for growth.

Profitability

Fair

Positive net income but low EPS may signal room for improvement.

Cash Flow Quality

Neutral

Negative free cash flow raises concerns about financial sustainability.

Leverage & Balance Sheet

Positive

Strong equity base with minimal debt supports financial stability.

Shareholder Returns

Neutral

No dividends and insufficient price history limit shareholder return assessment.

Analyst Sentiment & Valuation

Caution

Lack of current price and market performance data makes valuation difficult.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered a strong Q1 with $33.3M revenue (+22% YoY) and adjusted EBITDA of $3.3M (vs -$1.2M last year), raising full-year guidance to $133M-$135M revenue and $9M-$10M adjusted EBITDA. The clear operational momentum is record commercial execution (13 implementations; $4.5M-$5.0M annualized at steady state) plus improving RAC volume. However, the Q&A reveals the real pressure point: despite the upbeat quarter, adjusted EBITDA is expected to “start flirting with zero” in the middle of the year, driven by the cost ramp for New York State RAC and the decline of RAC Region 5. Management’s tone is confident and points to technology ROI (“as soon as this quarter”) and quarterly self-funding, but analyst questioning highlights a temporary profitability trough rather than a smooth ascent. Overall, the story is strong top-line recovery with near-term margin volatility as investment timing and program wind-down intersect.

AI IconGrowth Catalysts

  • 29% healthcare revenue growth YoY (total revenue $33.3M in Q1 2025)
  • Record 13 commercial program implementations in the quarter (expected $4.5M to $5.0M annualized revenue at steady state)
  • CMS RAC volume rebound in the quarter (initial validation of reversal of prior-year volume headwinds)
  • Eligibility revenue growth: ~$20% YoY (eligibility revenue $16.1M; contributed 48% of Q1 revenue)
  • Reallocation of focus from lower-margin RAC Region 5 to higher-value commercial business

Business Development

  • New York State Medicaid RAC implementation commenced in Q2 (first state Medicaid contract milestone)
  • CMS RAC RFP update: not selected for regions 3-5; however, 2 of 3 regions represented net new opportunities; Region 5 previously held and involved low-dollar DME/home health/hospice claims
  • Long-standing relationships referenced with CMS and HHS (including national contract with HHS Office of Inspector General; nationwide Medicare secondary payer contract; audit services in 25 states across two RAC regions)
  • Eligibility: displacement/expansion vs legacy vendors after first eligibility client signed in 2017; commercial eligibility partnerships operationalized in Q1

AI IconFinancial Highlights

  • Revenue: $33.3M in Q1 2025 (+22% YoY reported; +~30% YoY excluding $1.5M customer care revenue from prior-year quarter)
  • Claims auditing revenue: $17.1M (+38% YoY)
  • Eligibility revenue: $16.1M (+~20% YoY); eligibility contributed 48% of Q1 revenue
  • Adjusted EBITDA: +$3.3M in Q1 2025 vs -$1.2M in Q1 2024
  • Operating expenses: ~$33M in Q1 (+$2M vs year-ago) driven by scaling newer implementations and technology investments (Project Turing)
  • Guidance raised—Full-year 2025 revenue to $133M-$135M (raised bottom end to $133M); adjusted EBITDA to $9M-$10M (midpoint >2x 2024 adjusted EBITDA)
  • Profitability cadence shift: guidance implies adjusted EBITDA more weighted to 1st and 4th quarters due to RAC Region 5 wind down and increased expense ramp for New York State RAC

AI IconCapital Funding

  • No explicit buyback/debt/cash runway amounts disclosed in the transcript
  • Cash flow: positive $1.4M cash flow in Q1 2025 vs -$3.6M prior-year quarter
  • Management stated business moves toward being self-funded with positive free cash flow expected by end of 2025 into 2026

AI IconStrategy & Ops

  • Operational progress: streamline/accelerate implementation process enabling record 13 commercial program implementations
  • Technology: Project Turing described as multi-pronged AI/NLP-driven efficiency/accuracy initiative
  • ROI timing: initial product integrations seeing impact 'as soon as this quarter' with operationalization across 2025 to drive higher efficiency and expanded EBITDA margin
  • Second quarter operations: implementations team largely focused on New York State RAC contract (expected temporary dip in commercial implementations); New York RAC initial revenues estimated early 2026 if not sooner

AI IconMarket Outlook

  • Commercial: full-year commercial expectations unchanged; aim to meet/exceed ~$18M of additional annualized steady-state revenue from new implementations set in 2024 (despite temporary Q2 implementation dip)
  • Medicaid (NY): steady-state double-digit annualized revenue anticipated
  • RAC Region 5: wind down previously contemplated in beginning-of-year guidance (driving Q2 mid-year EBITDA pressure described in Q&A)
  • Adjusted EBITDA: committed to positive adjusted EBITDA every quarter; Q&A expectation that it may 'start flirting with zero' in the middle of the year but not turn negative

AI IconRisks & Headwinds

  • Mid-year adjusted EBITDA pressure: due to New York RAC implementation investment ramp plus decline of RAC Region 5 (risk of EBITDA nearing zero mid-year, but management expects positive each quarter)
  • RAC procurement outcome: not selected in recent CMS RAC RFP for regions 3-5 (mitigated by continued presence and net new opportunities in two regions; resources redeployed from Region 5 due to lower margins)
  • Implementation cycle normalization: management notes sales/implementation cycles normalizing after 2024 disruptions (implies prior volatility/headwind)
  • Tariffs/macro: management stated no material tariff impact because revenue is 100% domestic and expenses are domestic; federal contract cost structure is 100% domestic

Sentiment: MIXED

Note: This summary was synthesized by AI from the PHLT Q1 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Performant Healthcare, Inc. (PHLT) Financial Profile